98%
921
2 minutes
20
Background: Neuroimaging studies on major depressive disorder (MDD) have identified an extensive range of brain structural abnormalities, but the exact neural mechanisms associated with MDD remain elusive. Most previous studies were performed with voxel- or surface-based morphometry which were univariate methods without considering spatial information across voxels/vertices.
Methods: Brain morphology was investigated using voxel-based morphometry (VBM) and source-based morphometry (SBM) in 1082 MDD patients and 990 healthy controls (HCs) from the REST-meta-MDD Consortium. We first examined group differences in regional grey matter (GM) volumes and structural covariance networks between patients and HCs. We then compared first-episode, drug-naïve (FEDN) patients, and recurrent patients. Additionally, we assessed the effects of symptom severity and illness duration on brain alterations.
Results: VBM showed decreased GM volume in various regions in MDD patients including the superior temporal cortex, anterior and middle cingulate cortex, inferior frontal cortex, and precuneus. SBM returned differences only in the prefrontal network. Comparisons between FEDN and recurrent MDD patients showed no significant differences by VBM, but SBM showed greater decreases in prefrontal, basal ganglia, visual, and cerebellar networks in the recurrent group. Moreover, depression severity was associated with volumes in the inferior frontal gyrus and precuneus, as well as the prefrontal network.
Conclusions: Simultaneous application of VBM and SBM methods revealed brain alterations in MDD patients and specified differences between recurrent and FEDN patients, which tentatively provide an effective multivariate method to identify potential neurobiological markers for depression.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1017/S0033291722000320 | DOI Listing |
Neuro Endocrinol Lett
September 2025
Sichuan Provincial Center for Mental Health, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610072, China.
Background: Major depressive disorder (MDD) is associated with neuro-immune - metabolic - oxidative (NIMETOX) pathways.
Aims: To examine the connections among NIMETOX pathways in outpatient MDD (OMDD) with and without metabolic syndrome (MetS); and to determine the prevalence of NIMETOX aberrations in a cohort of OMDD patients.
Methods: We included 67 healthy controls and 66 OMDD patients and we assessed various NIMETOX pathways.
Trends Psychiatry Psychother
September 2025
Laboratory of Hormone Measurement, Department of Physiology and Behavior, Federal University of Rio Grande do Norte, Natal, Brazil. Postgraduate Program in Psychobiology, Center for Biosciences, Federal University of Rio Grande do Norte, Natal, Brazil. National Institute of Science and Technology fo
Background: Major Depressive Disorder (MDD) is a leading cause of global disability, contributing to substantial individual, social, and economic burdens. While antidepressant therapy remains the cornerstone of treatment, complementary lifestyle-based interventions, such as multimodal exercise and mindfulness, have shown promise in alleviating mood symptoms. However, their specific impact on sleep quality, a critical therapeutic target in MDD, remains underexplored.
View Article and Find Full Text PDFMetab Brain Dis
September 2025
Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1277, Jiefang Avenue, Wuhan, Hubei, 430022, China.
Major depression disorder (MDD) is a mental condition that significantly threatens both physical and psychological health. This study aimed to discern variances in plasma metabolic profiles between MDD sufferers and healthy counterparts. Additionally, we tracked the hospitalization journey of MDD patients to investigate the normalization of metabolic irregularities through conventional treatment in the form of self-control.
View Article and Find Full Text PDFFront Nutr
August 2025
Faculty of Medicine, Department of Psychiatry, Medical University of Gdańsk, Gdańsk, Poland.
Unlabelled: Mood disorders, including major depressive disorder (MDD) and bipolar disorder (BP), significantly impact global health, with MDD affecting over 300 million people and BP affecting approximately 2% of the world's population. Ketamine, originally an anesthetic, has emerged as a promising treatment for patients with treatment-resistant depression (TRD), due to its unique pharmacological properties, such as N-methyl-D-aspartate (NMDA) receptor antagonism and anti-inflammatory effects. The potential of ketamine in treating depression has sparked debate regarding its effects on appetite.
View Article and Find Full Text PDFAlpha Psychiatry
August 2025
Information Sciences and Technology, George Mason University, Fairfax, VA 22030, USA.
Background: Herein, we report on the initial development, progress, and future plans for an autonomous artificial intelligence (AI) system designed to manage major depressive disorder (MDD). The system is a web-based, patient-facing conversational AI that collects medical history, provides presumed diagnosis, recommends treatment, and coordinates care for patients with MDD.
Methods: The system includes seven components, five of which are complete and two are in development.